It is estimated that 0.5-1% of the UK population is infected with hepatitis C virus (HCV) and 170 million people worldwide. The commonest route of infection in the UK is injecting drug use, although there are still a significant number of people whose infection was contracted from infected blood products prior to the introduction of HCV screening in 1991. The virus is parenterally transmitted, so other risk factors include:
vertical transmission during childbirth transmission during medical procedures tattooing body piercing, and sexual transmission 1 .
Acute hepatitis C infection
In the vast majority of cases acute HCV infection is asymptomatic, leading to flulike symptoms in some subjects and clinical jaundice in less than 20%. Acute hepatitis C is rarely diagnosed, but if encountered should be treated promptly, as recent evidence has shown sustained viral clearance rates in excess of 90% 2 .
Chronic hepatitis C infection
Chronic infection is established in about 85% of those exposed and is often silent, which probably leads to underestimation of its prevalence. Common routes to diagnosis are: routine screening by the blood transfusion service direct request for testing from the patient incidental discovery of abnormal liver function tests during investigation of unrelated symptoms.
Chronic hepatitis C (CHC) infection is characterised by an immune-mediated hepatitis associated with progressive fibrosis. It is the severity and rate of progression of this fibrosis that dictates the mortality and morbidity associated with CHC. About one-third of patients have an indolent course to their disease lasting at least 30 years before significant fibrosis develops, but most of them will progress to significant liver fibrosis or cirrhosis within 20 years of infection 3 .
Assessment and management of chronic hepatitis C infection
The National Institute for Clinical Excellence (NICE) has recently issued guidance on the treatment of CHC 4 . These recommendations are consistent with guidelines from the European Association for the Study of the Liver 5 and the British Society of Gastroenterology 6 . Funding should now become more widely available for antiviral treatment in CHC. This article suggests a plan for the assessment and management of patients with HCV infection within the current healthcare climate.
Initial assessment of patients with chronic hepatitis C infection
When assessing a patient with CHC it is important to try to identify the duration of infection; this will give an indication of the rate of progression of the resultant liver disease.
History
A careful history obtained by an experienced practitioner (eg clinical nurse specialist) will usually reveal a likely risk factor. The history should assess symptoms attributable to CHC infection such as lethargy, malaise, abdominal and joint pains, in addition to symptoms of severe liver disease (eg encephalopathy, bruising, ascites). It is important to establish whether there is an ongoing risk factor for parenteral infections and/or any behaviour that would exacerbate the liver damage associated with CHC (eg excess alcohol consumption).
Concomitant disorders that might influence the course of disease or suitability for treatment should be sought at the time of initial assessment. These include a history of cardiovascular disease, autoimmune disorders and psychiatric illness (Table1).
Examination and investigations
Examination of patients with CHC should be directed at assessing their general health and identifying any stigmata of chronic liver disease.
Laboratory tests. Following clinical assessment, the diagnosis of HCV infection should be confirmed (Table 2) . If the patient is polymerase chain reaction (PCR) negative, the antibody status should be confirmed by recombinant immunoblot assay; if antibody positive and PCR negative on repeat testing, reassurance should be given that HCV has previously been cleared and there is no long-term risk of HCV related liver damage unless re-infected. It is, however, important to stress that they are not immune to future H CV infection.
Most patients who are antibody positive will also be PCR positive. The further tests required to assess the severity of any associated liver damage are shown in Table 2 . If CHC coexists with another liver disease, the pathologies can be synergistic. It is therefore usual to screen CHC patients for other common causes of liver disease. If there is evidence of cirrhosis, the patient should be regularly screened for primary hepatocellular carcinoma (HCC) as the risk is 3-5% per annum.
Liver biopsy. Liver biopsy plays an important role in the assessment of CHC infection. It is the only accurate way to assess the severity of liver damage attributable to HCV and also allows identification of any coexistent liver pathology. If liver biopsy is not contraindicated, it should be offered to all patients who would be considered candidates for antiviral therapy. The large multicentre randomised control treatment trials have included patients with moderate to severe liver damage, and the evidence base for treatment and response rates to therapy are based on this subgroup [7] [8] [9] . Patients in whom liver biopsy is contraindicated (eg haemophiliacs) must be assessed on clinical grounds alone.
Management of patients with chronic hepatitis C infection
Many hepatitis C patients are well informed and have expectations of how their disease should be managed, although some of the information available to the public on the worldwide web is inaccurate and misleading. Support and education are central to the management of these patients. For all patients attending a hepatitis C clinic, there should be a good source of accurate educational material available, such as leaflets from the British Liver Trust and trusted local support groups. The management of the patients should be multidisciplinary, with input from clinical nurse specialists, counsellors and addiction management experts when appropriate.
Harm reduction is necessary in all patients. This includes removal of risk factors for further infection and reduction of risk of transmission to their families, contacts and carers. In addition, any factor that could exacerbate the liver damage in CHC should be removed or minimised (ie venesection in iron overload, abstinence from alcohol). Every patient should be considered for antiviral treatment if they wish and assessed for the presence of contraindications, the majority of which are relative and should be appraised individually and regularly in each patient (Table 1) .
Patients with mild liver disease may be considered for entry into clinical trials such as the NHS Health Technologies Assessment study which is examining response rates to combination therapy in mild liver disease. Otherwise, sixmonthly or annual assessment is appropriate, allowing continuing education, support and re-appraisal. Re-biopsy may be useful 2-5 years after the initial biopsy to assess the rate of progression of the liver damage, but this is not essential.
Patients with decompensated cirrhosis should be seen more frequently in the clinic, as clinically indicated. It may be appropriate to screen them for HCC at 6-monthly intervals with liver ultrasound scan and serum alphafetoprotein 6 . A patient who is considered to be a possible candidate for liver transplantation should be referred to a transplant centre for assessment.
Antiviral therapy
The established current treatment for CHC is the combination of interferon (IFN) and ribavirin 10, 11 . NICE has recommended the use of this combination for the treatment of moderate to severe CHC liver damage in adults who:
have not previously been treated with combination therapy or have previously responded to IFN monotherapy but have since relapsed. 
Table 2. Tests used for the assessment of patients with chronic hepatitis C infection.
In patients who have a contraindication to ribavirin, polyethylene glycolylated (PEG) IFN is licensed for use as monotherapy, although this indication has not yet been considered by NICE. The efficacy of combination treatment is around 40% sustained virological response in all-comers. HCV exists as six different genotypes or strains, and subgroup analyses have shown that genotypes 2 and 3 are more sensitive to treatment 10, 11 . PEGylated IFN monotherapy achieves sustained virological response rates of around 30%, again with genotypes 2 and 3 more responsive to therapy 12 . PEGylated IFNs in combination with ribavirin have achieved sustained viral response rates of over 55%, with subgroups ranging from 25-85% or higher 13 . In addition to their enhanced efficacy, the need for administration only once weekly represents a significant benefit over standard IFN. Undoubtedly, regimens incorporating PEGylated IFNs will become established as the preferred choice of antiviral therapy.
There are considerable side effects from these drugs, of which the patients must be fully informed before embarking on a course of treatment (Table 3) .
Patients who fulfil the criteria for treatment and wish to proceed must have agreement from their local health authority to fund their treatment. The intention is to treat patients with genotype 1 or 4 for 48 weeks and all other genotypes for 24 weeks. In genotypes 1 and 4, if the PCR remains positive at 24 weeks of therapy, treatment is usually withdrawn as the chances of successful sustained virological response are negligible. (PCR negative at 24 weeks = sustained virological response.)
If there is no contraindication to therapy, the patient should be weighed to determine the required ribavirin dose (1,000 mg daily if <75 kg, 1,200 mg if >75 kg). It is important to inform the patient that ribavirin is teratogenic in expectant mothers and paternal sperm, and that two reliable forms of contraception should be used for the duration of treatment and the follow-up period. The initial dose of standard IFN is three million units thrice weekly subcutaneously. (It is important to note that the dose of PEGylated IFN may also be subject to weight-based adjustments.)
The patient should be taught to selfadminister IFN and should be monitored closely whilst on treatment. A typical monitoring schedule is shown in Table 4 . If blood tests or symptoms reveal problems, more frequent visits may be indicated.
Follow-up
After the end of treatment, the patient is seen at weeks 4 and 12 to ensure resolution of symptoms and side effects from therapy. If the patient was HCV PCR negative at the end of treatment, the PCR is repeated 24 weeks after treatment to assess whether there has been a sustained virological response.
Patients who are PCR positive at the end of treatment or 24 weeks later are classified as non-responders or relapsed responders. They should be followed in the clinic with regular reassessment of their liver disease, and may be offered further therapy if appropriate.
If there has been a sustained virological response, it is usual to follow the patient for at least a year after cessation of therapy and to confirm HCV negativity with further PCR tests and possibly a liver biopsy to assess histological change. It remains important to encourage these patients to avoid the risk of re-infection and to maintain a healthy lifestyle with low alcohol intake. 
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